Surgery Partners, Inc. (SGRY) स्टॉक विश्लेषण

कंपनी का अवलोकन

Surgery Partners, Inc. operates as a substantial entity within the United States healthcare sector, specifically focusing on the Medical Care Facilities industry. The organization owns and manages an extensive network of surgical facilities and ancillary services designed to deliver non-emergency surgical procedures across various medical specialties. This entity manages a significant workforce comprising approximately 16,000 employees, facilitating the delivery of ambulatory surgery center and surgical hospital services. With a market capitalization of $1.64 billion and annual revenue of $3.31 billion, the company holds a notable position in its sector. The market cap figure indicates that the market values the company's equity at a level that reflects its established operational scale and revenue generation capabilities. The revenue volume suggests a robust business model capable of sustaining operations for a large team while competing within the broader medical care landscape. These financial dimensions collectively establish Surgery Partners, Inc. as a major player in the provision of elective surgical care.

वित्तीय स्वास्थ्य

The company reported total revenue of $3.31 billion over the trailing twelve months, while recording a net income of -$77,900,000 and an EBITDA of $655.50 million. The substantial disparity between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, likely driven by the large employee base and facility costs, exceed gross profits before interest and taxes. Despite the net loss, the generation of $655.50 million in EBITDA demonstrates strong operational cash earnings before financing and non-cash charges. The company generated free cash flow of $164.71 million, which provides essential financial flexibility to fund capital expenditures or service its substantial debt obligations without immediate reliance on external financing. The gross margin stands at 23.1%, indicating that the company retains about a fifth of its revenue after direct costs of services are deducted. The operating margin of 15.1% shows the efficiency of the core business operations before interest and taxes, while the negative profit margin of -2.4% highlights the impact of interest expenses and other non-operating factors on the bottom line. In terms of leverage, the company holds $239.90 million in cash against total debt of $4.04 billion, resulting in a debt-to-equity ratio of 114.51. This high debt-to-equity ratio indicates that the balance sheet is highly leveraged, relying significantly on borrowed capital rather than shareholder equity. The current ratio of 1.87 suggests that the company possesses sufficient current assets to cover its short-term liabilities, indicating a healthy level of short-term liquidity. Return on equity is recorded at 2.8%, and return on assets is 3.7%, metrics that reveal the current effectiveness of management in generating profits relative to the capital invested and assets utilized, respectively.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio is listed as N/A due to the negative net income, whereas the forward P/E is 31.59. The absence of a trailing P/E combined with a high forward P/E implies that the market expects earnings to improve significantly in the future to justify the current valuation multiple. The price-to-book ratio is 0.95, indicating that the stock trades slightly below its book value, suggesting no significant market premium over the net asset value of the company. The price-to-sales ratio stands at 0.49, and the EV/EBITDA is 11.04, which are alternative valuation metrics that suggest the company is valued based on its sales revenue and enterprise earnings power rather than current profitability. The 52-week high is $24.18 and the 52-week low is $11.41. Without a specific current share price provided in the available facts to calculate the exact percentage, the range defines the volatility band within which the stock has traded over the last year. The beta value is 1.99, which indicates that the stock price is highly volatile and tends to move with significantly greater magnitude than the broader market index. This high beta suggests that the stock is sensitive to market fluctuations, potentially offering higher returns but also carrying elevated risk compared to less volatile healthcare peers.

Growth & Income

The revenue growth year-over-year is 2.4%, while the earnings growth year-over-year is N/A. Since earnings growth is not calculable due to the current net loss, it is impossible to determine if earnings are growing faster than revenue at this specific moment. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available earnings or cash flows back into the business for growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by steady revenue expansion without current profit distribution, relying instead on operational improvements and debt management to drive future value creation.